Phase 2 RCT | Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease.

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Respiratory Medicine

Commentary on Twitter

NEW Research—Pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD*

Being presented at #ERSCongress, ALERT 3 session, Sept 5 from 13:15 BST

From Joshua Solomon & colleagues https://t.co/Nu8wECECdD

*(please check study limitations) pic.twitter.com/IuRxLDZGd9

— The Lancet Respiratory Medicine (@LancetRespirMed) September 5, 2022